Hypomethylating drugs are useful in the management of Myelodysplastic syndromes, but there are only few reports on chronic myelomonocycitic (CMML) leukemia patients. We describe our experience in 3 CMML patients treated with azacitidine. Two patients obtained partial response after 4 treatment cycles with only minor toxicity and are in continuous partial response, with stable peripheral blood counts, at 29 and 30 cycles from treatment start.
Greco, M., Criscuolo, M., Fianchi, L., Fabiani, E., Pagano, L., Voso, M. T., 5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature, <<MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES>>, 2011; 3 (1): e2011011-e2011011. [doi:10.4084/MJHID.2011.011] [http://hdl.handle.net/10807/10333]
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature
Greco, Mariangela;Criscuolo, Marianna;Fianchi, Luana;Fabiani, Emiliano;Pagano, Livio;Voso, Maria Teresa
2011
Abstract
Hypomethylating drugs are useful in the management of Myelodysplastic syndromes, but there are only few reports on chronic myelomonocycitic (CMML) leukemia patients. We describe our experience in 3 CMML patients treated with azacitidine. Two patients obtained partial response after 4 treatment cycles with only minor toxicity and are in continuous partial response, with stable peripheral blood counts, at 29 and 30 cycles from treatment start.
| File | Dimensione | Formato | |
|---|---|---|---|
|
jdoe%2C+Greco317-1834-1-PB+%281%29.pdf
accesso aperto
Tipologia file ?:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
288.76 kB
Formato
Adobe PDF
|
288.76 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
